Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Alnylam Pharmace. buy DropStone

Start price
€111.28
03.11.20 / 50%
Target price
-
04.11.21
Performance (%)
-6.56%
End price
€103.98
06.01.21
Summary
This prediction ended on 06.01.21 with a price of €103.98. With a performance of -6.56%, the BUY prediction for Alnylam Pharmace. by DropStone closed slightly in the red. DropStone has 50% into this prediction

Alnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.

Performance without dividends (%)
Name 1w 1m 1y 3y
Alnylam Pharmace. -3.982% -3.982% -27.680% 17.508%
iShares Core DAX® -1.785% -1.250% 11.664% 12.714%
iShares Nasdaq 100 -2.154% 0.300% 37.531% 41.653%
iShares Nikkei 225® -4.028% -3.746% 17.142% 0.393%
iShares S&P 500 -1.969% 0.307% 25.617% 40.084%

Comments by DropStone for this prediction

In the thread Alnylam Pharmace. diskutieren

Buy Alnylam Pharmace.

In the thread Trading Alnylam Pharmace.
Prediction Buy
Perf. (%) -6.56%
Target price
Change
Ends at 04.11.21

Buy beendet